| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 17, 2023 |
| Accession Number: | 0001193125-23-185162 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2022 | Buy → Neutral | H.C. Wainwright | |
| 9/21/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
| 8/5/2021 | $12.00 → $10.00 | Buy | HC Wainwright & Co. |
H.C. Wainwright downgraded Clovis Oncology from Buy to Neutral
HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $9.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously